GeneTex
United States (US)

MDM2 antibody [2A10]

MDM2-antibody-2A10-GTX16895-WB-1_18121411_494.jpg
GTX16895_WB_18121410_478.jpg

Cat No. GTX16895

Host Mouse
Clonality Monoclonal
Clone Name 2A10
Isotype IgG2a
Application WB, ICC/IF, IHC-P, IP
Reactivity Human
APPLICATION

Application Note

For IF: Use at a concentration of 1 μg/ml. For IHC-P: Use at a concentration of 2.5 μg/ml (heat pre-treatment required). For IP: Use at an assay dependent dilution. For WB: Use at a dilution of 1:50-1:500. Optimal dilutions/concentrations should be determined by the researcher.

Calculated MW

~90kD kDa. ( Note )

Positive Control

A549 , H1299
PROPERTIES

Form

Liquid

Buffer

50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5, containing 0.1% sodium aizide

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.

Concentration

0.1 mg/ml (Please refer to the vial label for the specific concentration.)

Antigen Species

Human

Immunogen

Human MDM2 protein

Purification

Purified

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Mdm2 Proto-Oncogene,Actfs,Hdmx,Hdm2,Mdm2

Background

Increased expression of proto-oncogenes due to gene amplification can lead to cellular transformation in the absence of other mutagenic events. Recently, a novel gene termed MDM2, first identified in mouse as a small acentromeric extrachromosomal element, was shown to become oncogenic upon amplification and tumorigenic when overexpressed in NIH3T3 and Rat2 cells. The human homolog of MDM2 gene has been isolated and mapped to chromosome 12q13-q14, a region that is found to be amplified in human sarcomas. Sequence analysis of the murine, rat, and human MDM2 genes suggests that MDM2 may be involved in transcriptional regulation. MDM2 contains two putative metal-binding motifs, one of which shares similarity to known zinc finger transcriptional activators. MDM2 also contains a putative nuclear localization signal and an acidic domain of the type found in transcriptional activators. A functional role for MDM2 has recently been identified on the basis of experiments which demonstrate that MDM2 forms a stable complex with p53 in vivo. Furthermore, over-expression of MDM2 inhibits the ability of wild type p53 to stimulate expression of target genes, and this inhibition appears to result from MDM2 binding to the acidic activation domain of p53, thereby preventing p53 from directly contacting the transcriptional machinery. Interestingly, wild type p53 appears to positively regulate expression of the MDM2 gene. MDM2 amplification has been observed in sarcomas, and direct analysis of the MDM2 and p53 genes in sarcomas indicates that one or the other but not both of these genes is mutated in 70% of the tumors. Thus, it appears that genetic alterations in either p53 or MDM2 represent alternative mechanisms for inactivating the same growth suppressive pathway. Regulation of MDM2 expression by p53 also represents a potential feed back control of p53 function.

Database

Research Area

DATA IMAGES
MDM2-antibody-2A10-GTX16895-WB-1_18121411_494.jpg

GTX16895 WB Image

Detection of human MDM2 by immunoblotting. Sample: Whole cell lysate from A549 cells. Primary antibody: Anti-MDM2 Mouse mAb (2A10) (CTX16895) (2 μg/ml). Detection: chemiluminescence.

GTX16895_WB_18121410_478.jpg

GTX16895 WB Image

MDM2 antibody [2A10] detects MDM2 protein by western blot analysis.
A. 30 μg Jurkat whole cell lysate/extract
B. 30 μgRaji whole cell lysate/extract
C. 30 μg NCI-H929 whole cell lysate/extract
7.5 % SDS-PAGE
MDM2 antibody [2A10] (GTX16895) dilution: 1:500

Package List Price ($)
$ 319